Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

GPC Biotech, Agennix To Merge

by Lisa M. Jarvis
February 23, 2009 | A version of this story appeared in Volume 87, Issue 8

GPC Biotech, in Munich, and Houston-based Agennix have agreed to merge to expand and sustain their oncology pipelines. The new German company will receive a $19 million cash infusion from the investment firm of Dietmar Hopp, who is cofounder of software firm SAP and a major shareholder in GPC Biotech. For GPC Biotech, the deal is part of an effort to rebuild after a series of setbacks for its lead prostate cancer treatment, satraplatin. For Agennix, the merger will help accelerate the development of its lead cancer drug, talactoferrin, which is a recombinant form of human lactoferrin, currently in Phase III trials for treatment of lung cancer.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.